XM अमेरिका के निवासियों को अपनी सेवाएँ मुहैया नहीं करता है।
B
B

BayerAG


समाचार

Bayer Ct Injection System Medrad® Centargo Receives FDA Clearance

BRIEF-Bayer Ct Injection System Medrad® Centargo Receives FDA Clearance Nov 7 (Reuters) - BAYER AG BAYGn.DE : CT INJECTION SYSTEM MEDRAD® CENTARGO FROM BAYER RECEIVES FDA CLEARANCE Further company coverage: [BAYGn.DE] (Gdansk Newsroom)
B

Corteva reports larger-than-expected loss, cuts full-year sales outlook

UPDATE 2-Corteva reports larger-than-expected loss, cuts full-year sales outlook Adds details throughout Nov 6 (Reuters) - U.S. agrichemicals firm Corteva CTVA.N reported a larger-than-expected loss on Wednesday, hurt by lower sales and prices, leading the company to cut its full-year sales outlook and sending its shares down over 10% after market close.
B
B
C

India economic, corporate events on November 1

DIARY- India economic, corporate events on November 1 BENGALURU, Nov 1 (Reuters) - Diary of India economic, corporate events on November 1. ECONOMIC, CORPORATE .BSE500 EVENTS: RIC Local Start Date Local Time Indicator Name Period Reuters Poll Prior INLOAN=ECI 1 Nov 2024 17:00 Bank Loan Growth 18 Oct, w/e 12.8% INDEP=ECI 1 Nov 2024 17:00 Deposit Growth 18 Oct, w/e 11.8% INFXR=ECI 1 Nov 2024 17:00 FX Reserves, USD 25 Oct, w/e 688.27B Start Date Start Time RIC Company Name Event Name 01-Nov-2024 NT
B

Regeneron shares drop as higher-dose Eylea drug misses sales estimates

UPDATE 1-Regeneron shares drop as higher-dose Eylea drug misses sales estimates Rewrites throughout to add details on higher dose version of Eylea By Christy Santhosh Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O o n Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease drug Eylea, sending its shares down 9%.
B
R
R
S

Regeneron beats results estimates on demand for eczema treatment, eye drug

Regeneron beats results estimates on demand for eczema treatment, eye drug Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea. Regeneron has been looking to upgrade patients who use Eylea to a high-dose version, as the drug that has long been its cash cow faces the threat of biosimilar products and stiff comp
B
R
R
S

FMC beats third-quarter profit estimates on strong North America sales, lower costs

FMC beats third-quarter profit estimates on strong North America sales, lower costs Oct 29 (Reuters) - Agrichemicals firm FMC FMC.N beat Wall Street estimates for quarterly profit on Tuesday, helped by strong sales in North America and lower costs. FMC, which makes insecticide and fungicide, had seen a sharp drop in demand in 2023 as high inventory levels of crop chemicals across several regions had weighed in on earnings.
B
B
F

Ukrainian corn seed flows to Europe in further farm trade shift

ANALYSIS-Ukrainian corn seed flows to Europe in further farm trade shift Corn seed part of rise in Ukrainian farm exports to EU EU regulatory clearance and war fuelled seed trade EU growers fear competition, Ukraine sees own import reliance By Gus Trompiz and Pavel Polityuk PARIS/KYIV, Oct 24 (Reuters) - Ukraine has rapidly expanded exports of corn seed to the EU in the past two years in rare good news for its war-hit agricultural sector but adding to European farmers' grievances about what they
B
C

Bayer And Dewpoint Therapeutics Sign Licensing Agreement For Heart Disease Program

BRIEF-Bayer And Dewpoint Therapeutics Sign Licensing Agreement For Heart Disease Program Oct 24 (Reuters) - BAYER AG BAYGn.DE : BAYER AND DEWPOINT THERAPEUTICS SIGN LICENSING AGREEMENT FOR HEART DISEASE PROGRAM POST-LICENSING, COMPANIES WILL CONTINUE TO COLLABORATE ON CARDIOVASCULAR AND RENAL PROGRAMS DEWPOINT WILL RECEIVE AN UPFRONT AND ADDITIONAL
B

Bayer Announces Partnership With Impli

BRIEF-Bayer Announces Partnership With Impli Oct 24 (Reuters) - Bayer AG BAYGn.DE : BAYER AG - ANNOUNCED A PARTNERSHIP WITH IMPLI, AN INNOVATIVE, DEEP-TECH START-UP IN PRECISION CARE Further company coverage: [BAYGn.DE] (Gdansk Newsroom)
B

Shell setback upsets Nigeria's quest to lure investment

ANALYSIS-Shell setback upsets Nigeria's quest to lure investment Exxon Mobil decision was approved but after long wait Shell has not commented and regulator has not explained Some investors see positive change By MacDonald Dzirutwe LAGOS, Oct 23 (Reuters) - Nigeria's decision this week to block Shell's SHEL.L $2.4 billion sale of its onshore assets has sent a negative signal to investors the country urgently needs to strengthen its all-important oil sector, analysts said.
B
G

Ashmore, Biomerieux, Diasorin

EUROPE RESEARCH ROUNDUP-Ashmore, Biomerieux, Diasorin Oct 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Ashmore, Biomerieux and Diasorin, on Thursday. HIGHLIGHTS * Ashmore ASHM.L : JP Morgan raises target price to 161p from 155p * Biomerieux BIOX.PA : HSBC raises target price to EUR 126 from EUR 120 * Diasorin DIAS.MI : HSBC cuts to hold from buy * Givaudan SA GIVN.S : Citigroup cuts target price to CHF 4650 from CHF 4750 * Oxf
A
A
A
A
B
B
C
D
E
E
G
G
I
L
L
S
T
W
Q
A
A
A
D
U

Australia's Enlitic gains on distribution deal with Bayer Healthcare

BUZZ-Australia's Enlitic gains on distribution deal with Bayer Healthcare ** Shares of Enlitic ENL.AX rise 14.1% to A$0.073, set for best day since Sept. 30, if current gains hold ** Healthcare technology firm says it has signed a three-year distribution contract with multinational biomedical co Bayer Healthcare ** Under the contract, Enlitic says
B

Bayer submits EU marketing application for menopause relief drug

Bayer submits EU marketing application for menopause relief drug Oct 15 (Reuters) - Bayer BAYGn.DE on Tuesday said it had applied for marketing authorization with the European Medicines Agency (EMA) for its menopause relief drug elinzanetant. The daily pill was shown to ease hot flashes in a third late-stage trial that provided supporting data on efficacy and long-term safety.
B

Bayer applies for third indication of Nubeqa in EU

Bayer applies for third indication of Nubeqa in EU BERLIN, Oct 14 (Reuters) - Bayer BAYGn.DE said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as darolutamide, in combination with androgen deprivation therapy. It said the submission to the European Medicines Agency (EMA) was based on positive results from a phase III trial that showed darolutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of radiological progression or d
B

Bayer Submits Application For Third Indication Of Darolutamide In EU

BRIEF-Bayer Submits Application For Third Indication Of Darolutamide In EU Oct 14 (Reuters) - BAYER AG BAYGn.DE : SUBMITS APPLICATION FOR THIRD INDICATION OF DAROLUTAMIDE IN EU IS SEEKING APPROVAL FOR USE OF DAROLUTAMIDE IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) SUBM
B

Bayer slips after verdict to pay $78 mln in Roundup cancer case

BUZZ-Bayer slips after verdict to pay $78 mln in Roundup cancer case ** Shares of Germany's Bayer BAYGn.DE slip 1.7% after a state court jury in Philadelphia found the company must pay $78 million in latest Roundup cancer trial ** The verdict follows previous consecutive victories for Bayer in that court ** New setback after PCB review, a local tra
B

US judicial panel to examine litigation finance disclosure

UPDATE 1-US judicial panel to examine litigation finance disclosure Adds comment from litigation funding group in paragraph 16 By Nate Raymond Oct 10 (Reuters) - A federal judicial rules-making panel on Thursday agreed to study whether a nationwide rule requiring disclosure of third-party litigation funding in lawsuits is necessary at the urging of major companies, business groups and Republican lawmakers .
A
B
C
G
N
P

US judicial panel to examine litigation finance disclosure

US judicial panel to examine litigation finance disclosure By Nate Raymond Oct 10 (Reuters) - A federal judicial rules-making panel on Thursday agreed to study whether a nationwide rule requiring disclosure of third-party litigation funding in lawsuits is necessary at the urging of major companies, business groups and Republican lawmakers . After a decade of weighing whether it should do anything to regulate the emerging field of litigation finance, the U.S.
A
B
C
G
N
P

Bayer must pay $78 million in latest Roundup cancer trial, jury finds

UPDATE 2-Bayer must pay $78 million in latest Roundup cancer trial, jury finds Adds statement from plaintiffs' lawyers in paragraphs 3-4, background in paragraph 10 By Brendan Pierson Oct 10 (Reuters) - Bayer BAYGn.DE must pay $78 million to a Pennsylvania man who said he got cancer from using the company's Roundup weedkiller, a state court jury in Philadelphia found on Thursday.
B

Bayer must pay $78 mln in latest Roundup cancer trial, jury finds

Bayer must pay $78 mln in latest Roundup cancer trial, jury finds By Brendan Pierson Oct 10 (Reuters) - Bayer BAYGn.DE must pay $78 million to a Pennsylvania man who said he got cancer from using the company's Roundup weedkiller, a state court jury in Philadelphia found on Thursday. The verdict in state court in Philadelphia follows previous consecutive victories for Bayer in that court.
B



स्थितियाँ

लोकप्रिय परिसंपत्तियाँ

अस्वीकरण: XM Group के सत्व केवल निष्पादन वाली सेवा और हमारी ऑनलाइन व्यापार सुविधा में पहुँच प्रदान करते हैं, ताकि व्यक्ति वेबसाइट पर या उसके जरिए उपलब्ध सामग्री को देख सके और/या उसका उपयोग कर सके। इसका प्रयोजन इसे बदलना या विस्तार देना नहीं है, न ही वह इसे बदलता या विस्तार देता है। इस तरह की पहुँच हमेशा ही निम्नलिखित के अधीन रहेगी: (1) नियम और शर्तें; (2) जोखिम चेतावनियाँ; और (3) पूर्ण अस्वीकरण। इसलिए ऐसी जानकारी सामान्य सूचना से अधिक कुछ भी नहीं है। विशेष रूप से, कृपया इससे अवगत रहें कि हमारी ऑनलाइन व्यापार सुविधा की सामग्रियाँ न तो किसी चीज का अनुरोध करती हैं, न ही वित्तीय बाजारों में प्रवेश करने की पेशकश ही करती हैं। किसी भी वित्तीय बाजार में व्यापार करने के साथ आपकी पूँजी को उल्लेखनीय जोखिम है।

हमारी ऑनलाइन व्यापार सुविधा में प्रकाशित सभी सामग्रियाँ शैक्षणिक/सूचनात्मक प्रयोजनों मात्र के लिए हैं, और इनमें वित्तीय, निवेश टैक्स या व्यापार सलाह और सुझाव नहीं हैं - न ही ऐसा समझना चाहिए कि इनमें ये सब हैं; न ही इनमें हमारी व्यापार कीमतों का अभिलेख है; न ही इनमें किसी वित्तीय उपकरण में लेन-देन करने का निमंत्रण या अनुरोध है; न ही ये आपको अवांछित वित्तयी प्रोमोशन पेश करती हैं।

इस वेबसाइट में मौजूद कोई भी तृतीय पक्षीय सामग्री, तथा XM द्वारा तैयार की गई सामग्रियाँ, जैसे: अभिप्राय, समाचार, अनुसंधान, विश्लेषण, कीमतें और अन्य सूचनाएँ या तृतीय पक्षों की साइटों के लिंक, "जैसा-है-वैसा" के आधार पर बाजार के बारे में सामान्य टिप्पणी के रूप में उपलब्ध कराई गई हैं, और वे निवेश हेतु सलाह नहीं हैं। जिस हद तक कीसी सामग्री को निवेश अनुसंधान मान लिया जाता है, उस हद तक आपको ध्यान में रखना होगा और इसे स्वीकार करना होगा कि वह सामग्री इस उद्देश्य से और निवेश अनुसंधान की स्वतंत्रता को बढ़ावा देने के लिए कानूनी आवश्यकताओं के मुताबिक, तैयार नहीं की गई है, और इसलिए उसे प्रासंगिक कानूनों और विनियमों के तहत विपणन संप्रेषण माना जाएगा। कृपया सुनिश्चित करें कि आपने गैर-आश्रित निवेश के बारे में हमारी सूचना को पढ़ और समझ लिया है। पीछे दी गई जानकारी के बारे में अनुसंधान और जोखिम चेतावनी यहाँ उपलब्ध है।

जोखिम की चेतावनी: आपकी पूँजी जोखिम में है। लीवरेज वाले उत्पाद सबके उपयुक्त नहीं होते हैं। कृपया हमारे जोखिम खुलासे पर विचार करें।